<DOC>
	<DOC>NCT03025308</DOC>
	<brief_summary>The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the parent studies of filgotinib in rheumatoid arthritis (RA).</brief_summary>
	<brief_title>Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Key Males or females who may benefit from filgotinib as judged by the investigator AND who completed a Gilead sponsored filgotinib parent study for RA as outlined below: Have completed GSUS4170301, GSUS4170302 or GSUS4170303 on study drug OR Have completed GSUS4170302 on standard of care therapy due to RA nonresponder status Females of childbearing potential must have a negative pregnancy test prior to first dose of study drug in the long term extension (LTE) Males and females of childbearing potential who engage in heterosexual intercourse must agree to protocolapproved methods of contraception Key Diagnosis of an autoimmune or inflammatory joint disease other than RA, which would put the participant at risk by participating in the study or would interfere with study assessments/data interpretation, per judgment of the investigator Known hypersensitivity to the study drug or its excipients Any medical condition which would put the participant at risk by participating in the study or would interfere with study assessments/data interpretation, per judgment of the investigator NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>